10.03.24 -- A Supply-Chain Woman Of Iran

This webinar will focus on how KBI Biopharma's SUREtechnology Platform™, powered by Selexis®, enables rapid advancement of new complex biologics from early development to first-in-human (FIH). Register to learn how the integration of the SUREtechnology Platform™ accelerates the creation of high-performing, stable cell lines tailored for biologics production. Learn more here.

Manufacturing therapeutic cells includes labor-intensive processes. These researchers are developing a way to increase yields through cost-effective expansion protocols.

Explore key process operations, some of the challenges in manufacturing high-concentration biologics, and factors to consider for process optimization.

Biomarkers are vital for early neurodegenerative disease diagnosis. Learn about key protein biomarkers, clinicopathologic correlations, and measurement strategies.

Regarding bispecific antibody (BsAb) manufacturing, a well-optimized culture environment is essential for achieving high and consistent BsAb yields with the desired critical quality attributes.

To execute complex viral product manufacturing, a service provider needs expertise in adherent cell culture capabilities, cell line productivity, and the intricacies associated with these products.

Uncover how N-1 process development can lead to significant improvements in mAb production processes and review considerations for successfully implementing N-1 process development.

See how this integrated CLD approach, combined with cutting-edge technologies, can drive program success and accelerate the development of protein-based therapeutics.

Consider the advantages of dual-sourcing in pharmaceutical fill/finish and how this approach can bolster supply chain resilience, increase capacity, and accelerate commercialization.

Iwan Bertholjotti, director of commercial bioconjugate development, and Dr. Bernhard Stump, head of bioconjugate development, address the complexity and uncertainty in bioconjugates.

An experienced contract manufacturer can help drug developers to better utilize internal resources, leverage deep industry experience, and mitigate risk across development cycles.

Join the next Outsourced Pharma Live as our panel explores the critical considerations and best practices for selecting and managing CDMOs in the development of novel therapies, including advanced therapy medicinal products like cell and gene therapies. Industry experts will share insights on evaluating CDMO capabilities, ensuring quality and compliance, and fostering effective partnerships to accelerate innovation while mitigating risks.

With extensive experience and capabilities, we foster a collaborative environment, developing and implementing innovative analytical methods to address our partners' testing needs.

Review how bYlok technology can drive correct heavy-light chain pairing to >95% and how you can access it via a license agreement to overcome industry-wide challenges.

Unearth how leveraging cross-functional teamwork helped complete a cold chain infrastructure expansion in a fraction of the expected timeline.

We are an established leader in advancing vaccines from preclinical development to commercial supply across multiple modalities.

Gain insights into boosting efficiency, fostering innovation, and how integrated capabilities generate value for innovators.

It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets. In fact, he still wields a scalpel quite frequently, and on the Business of Biotech podcast, he offers a fantastic reason why. Whether you're a biotech builder in the throes of disruption, or feeling lucky that you've been threading scientific, clinical, capital, and regulatory needles all along, this episode offers a ton of insight.